Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Questcor Pharmaceuticals

Share:
Related QCOR
Mallinckrodt Is No Valeant-Philidor Situation, Morgan Stanley Says
There's A Reason Mallinckrodt Continues To Disclose A Protracted, Multi-Agency Probe Of Recently-Acquired Questcor Pharmaceuticals

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Questcor Pharmaceuticals (NASDAQ: QCOR), and raised its price target from $28.00 to $30.00.

Jefferies noted, “QCOR beat Q3 revenue and GAAP EPS consensus driven by higher Acthar sales and lower OpEx. Curiously, mgmt has decided to end its monthly disclosure of Acthar Rx citing sales have reached a ‘mature' level, however, mgmt will allow pharmacy distributors to release Rx data to third party providers. We are raising our PT to $30 on lower OpEx and share count, offset by a slight decrease in Acthar sales.”

Questcor Pharmaceuticals closed on Tuesday at $25.93.

Latest Ratings for QCOR

DateFirmActionFromTo
May 2014Mizuho DowngradesBuyNeutral
May 2014PiperJaffrayDowngradesOverweightNeutral
Apr 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for QCOR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (QCOR)

View Comments and Join the Discussion!